E-mail: mayer.Jiri@fnbrno.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikované knihy
- Leukemie
- Postižení plic u imunokompromitovaných nemocných : diferenciální diagnostika a využití bronchoaveolární laváže
- Vysokodávkovaná chemoterapie s transplantací kmenových krvetvorných buněk v komplexní léčbě zhoubných nádorů
- Vysokodávkovaná protinádorová chemoterapie s transplantací krvetvorných buněk : informace pro nemocné
- Folikulární lymfomy
- Klinické využití chimerické monoklonální protilátky rituximab
- Vysokodávkovaná protinádorová chemoterapie s transplantací krvetvorných buněk
- Molekulární hematologie
- Transplantace kostní dřeně a periferních hematopoetických buněk
Publikovaná abstrakta
- 13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS
- A NOVEL MGB PROBE-BASED ASSESSMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA CARRYING NPM1 (NUCLEOPHOSMIN) EXON 12 MUTATIONS
- A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma
- A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.
- A Randomized Prospective Multicenter Phase III Trial Comparing Standard GvHD Prophylaxis with Cyclosporine and Methotrexate with Additional Pretransplant ATG Fresenius (ATG-F) in Allogeneic Stem Cell Transplantation from Matched Unrelated Donors
- A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial
- ABNORMALITY OF GLUCOSE AND LIPID METABOLISM DURING NILOTINIB THERAPY – RESULTS OF ENIGMA 2 STUDY
- Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL)
- Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL)
- ACUTE LYMPHOBLASTIC LEUKEMIA IN THE ELDERLY: A TOUGH ONE
- ACUTE MYELOID LEUKEMIAS WITH RECURRENT GENETIC ABNORMALITIES: FREQUENT ASSESSMENT OF MINIMAL RESIDUAL DISEASE AND TREATMENT OF MOLECULAR RELAPSE
- Alemtuzumab (CAMPATH®, MABCAMPATH®, ) Has Superior Progression Free Survival (PFS) vs Chlorambucil as Front-Line Therapy for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (BCLL).
- Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma: Data from National Czech Registry.
- Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with Normal Karyotype: A Risk Factor Analysis in 247 Patients, Based On Molecular Markers and Stage at Transplantation
- ALLOGENEIC STEM CELL TRANSPLANTATIONS AFTER REDUCED INTENSITY CONDITIONING REGIMEN FLUDARABIN, BUSULFAN AND ATG (FRESENIUS)
- AN ATYPICAL JUNCTION OF BCR-ABL GENE AS MOLECULAR MARKER FOR QUANTITATIVE MONITORING OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
- AN EXPLORATORY ANALYSIS FROM 3-YEAR DASISION FOLLOW-UP EXAMINING THE IMPACT ON PATIENT OUTCOMES OF EARLY COMPLETE CYTOGENETIC RESPONSE AT 3 MONTHS AND MAJOR MOLECULAR RESPONSE AT 12 MONTHS
- ANALYSIS OF 1458 ACUTE MYELOID LEUKEMIA FROM THE ALERT PROJECT (ACUTE LEUKEMIA CLINICAL REGISTER) IN THE CZECH REPUBLIC IN 1996-2006
- ANALYSIS OF MERKEL CELL POLYOMAVIRUS PROGNOSTIC SIGNIFICANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA
- ANALYSIS OF POTENTIALLY BICLONAL CLL PATIENTS WITH TWO OR THREE PRODUCTIVE IGH REARRANGEMENTS
- ANALYSIS OF TREATMENT AND OUTCOME DATA OF 2904 PATIENTS FROM THE EUTOS POPULATION-BASED REGISTRY
- ANALYSIS OF TREATMENT OUTCOME OF ALL PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA (APL): NO DIFFERENCE IN SURVIVAL BEFORE AND AFTER ATRA ERA
- Analýza genové exprese u folikulárního lymfomu pomocí oligonukleotidových microarrays
- Apoptosis in Chronic Myeloid Leukemia Cells Transiently Treated with Imatinib or Dasatinib Is Caused by Residual BCR-ABL Kinase Inhibition
- ARE MUTATIONS IN THE IDH2 GENE SUITABLE MOLECULAR MARKERS FOR MRD MONITORING IN AML PATIENTS?
- ATM INACTIVATION DISTURBS ATM-P53 PATHWAY IN RESPONSE TO DNA DAMAGE INDUCED BY DOXORUBICIN BUT NOT FLUDARABINE IN CLL CELLS
- AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: STILL NOT OUT OF FASHION
- AUTONOMIC DYSFUNCTION IS AUGMENTED DURING THERAPY, BUT CAN BE IMPROVED BY PHYSICAL EXERCISE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY. RESULTS OF A PILOT TRIAL.
- Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials
- BIOLOGICAL AND CLINICAL RELEVANCE OF MIRNAS INDUCED IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS DURING ADMINISTRATION OF THERAPY IN VIVO AND IN VITRO
- BONE MARROW VERSUS PERIPHERAL BLOOD: COMPARISON OF THE CHIMERISM ANALYSIS
- Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study
- BORTEZOMIB-RITUXIMAB RESULTS IN IMPROVED PFS AND RESPONSE RATES VERSUS RITUXIMAB, AND QUALITY OF RESPONSE IS ASSOCIATED WITH IMPROVED OUTCOMES, IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA (FL)
- CD26 ANTIGEN IS SPECIFIC FOR LEUKEMIC STEM CELLS IN CHRONIC MYELOID LEUKEMIA AND DISTINGUISHES PATIENT GROUPS WITH DIFFERENT RATIOS OF LEUKEMIC AND HEALTHY STEM CELL
- CD52 ANTIGEN IS EXPRESSED AT DIFFERENT INTENSITIES ON TUMOR CELLS OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA, SMALL LYMPHOCYTIC LYMPHOMA, MANTLE CELL LYMPHOMA AND ON CD34+ CELLS
- CEBPA GENE MUTATIONAL STATUS: A COMPLETE SCREENING USING HIGH-RESOLUTION MELT CURVE ANALYSIS
- Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy
- Clinical Manifestation of 1000 Leukemias
- Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study within Various Cytogenetic Risk Categories
- CLINICAL VALUE OF SCREENING DETECTION OF 1,3-BETA-D GLUCAN (BG) FOR EARLY DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS (IFI) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES - RESULTS OF A PROSPECTIVE STUDY
- CLL-SPECIFIC RESEQUENCING MICROARRAY AS A TOOL FOR CLL RESEARCH AND DIAGNOSTICS
- CLOFARABINE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA – SINGLE CENTER EXPERIENCE
- Clonal Evolution and Therapy Related Selection Of TP53 Mutations In Chronic Lymphocytic Leukemia Patients
- Clonal Evolution of Malignant Populations In Potentially Biclonal Chronic Lymphocytic Leukemia Patients
- CLOSTRIDIUM DIFFICILE INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY IN CZECH AND SLOVAK REPUBLIC – A RETROSPECTIVE ANALYSIS
- CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry
- Combination Of Lenalidomide, Dexamethasone and Cyclophosphamide as Treatment For The First Relapse Of Multiple Myeloma: Efficacy, Toxicity and Occurance Of Thyroid Abnormalities
- COMPARISON OF GALACTOMANNAN DETECTED IN SERUM/ BRONCHOALVEOLAR LAVAGE FLUID AND TYPE OF ABNORMALITY ON PULMONARY HIGH RESOLUTION COMPUTER TOMOGRAPHY IN PATIENTS WITH PULMONARY INVASIVE ASPERGILLOSIS
- Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study
- COMPARISON OF TWO METHODS OF HEMATOPOIETIC STEM CELL ISOLATION AND EVALUATION OF THE EX VIVO CULTURED AND DIFFERENTIATED CELLS WITH CDNA MICROARRAYS
- COMPLETE HEMATOLOGIC REMISSION BUT NOT MOLECULAR REMISSION IS ASSOCIATED WITH PROLONGED SURVIVAL IN PATIENTS WITH ACUTE LEUKEMIA BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Constitutive Activation of STAT1 and STAT3 Proteins on Serine and Tyrosine Residues Were Found in Majority of CLL
- CONSTITUTIVE ACTIVATION OF STAT1 AND STAT3 PROTEINS WITHOUT INTERFERON INDUCIBILITY: RELEVANCE TO THERAPY IN IGVH-UNMUTATED CLL PATIENTS
- CONTRIBUTION OF GALACTOMANNAN DETECTION FOR EARLY DIAGNOSIS OF INVASIVE ASPERGILLOSIS IN DIFFERENT GROUPS OF HEMATOONCOLOGICAL PATIENTS
- Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab
- Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy
- Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
- DASATINIB EFFICACY AND TOLERANCE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT/INTOLERANT TO IMATINIB IN THE CONTEXT OF REAL CLINICAL PRACTICE MANAGEMENT
- Dasatinib Promotes BIM Dependent Apoptosis Via MEK/ERK without Need for Permanent BCR-ABL Inhibition
- DEEP SEQUENCING IDENTIFIES TP53 MUTATIONS BEFORE THEIR CLONAL SELECTION BY THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
- Defects of ATM Gene Involving Mutation Lead to Complete Elimination of ATM Function in Chronic Lymphocytic Leukemia
- DEFINITION AND VALIDATION OF NOVEL PROGNOSTIC MARKERS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
- Detail Characterization of 22q11 Deletion and Mir-650 Role in CLL Patients
- DETAILED MUTATIONAL ANALYSIS OF TP53 GENE REVEALS HIGH INCIDENCE OF ADDITIONAL MINOR PROPORTION MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
- Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1, CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression.
- DETECTION OF AN ABERRANT FORM OF E13A2 BCR-ABL TRANSCRIPT CAUSING FAILURE OF MOLECULAR DIAGNOSTICS IN PATIENT WITH CHRONIC MYELOID LEUKEMIA (CML)
- DETECTION OF MINIMAL RESIDUAL DISEASE IN PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA USING BOTH FOUR-COLOR AND EIGHT-COLOR FLOW CYTOMETRY AND QUANTITATIVE REAL TIME PCR APPROACH
- Detection of Molecular Relapse of AML by Very Frequent Quantitative Monitoring of Different Molecular Markers (Fusion Transcripts and WT1) in Different Compartments (Peripheral Blood-PB, Bone Marrow-BM, and Selected CD34+ Bone Marrow Cells) and Its..
- DETECTION OF MOLECULAR RELAPSE OF AML BY VERY FREQUENT QUANTITATIVE MONITORING OF DIFFERENT MOLECULAR MARKERS IN DIFFERENT COMPARTMENTS AND ITS TREATMENT WITH CHEMOTHERAPY OR GEMTUZUMAB OZOGAMICIN
- Detekce herpetických virů u imunokompromitovaných pacientů metodou „real-time“ PCR
- DIAGNOSIS AND TREATMENT OF MALIGNANT LYMPHOMAS IN PREGNANCY AND LACTATION, OUR OWN EXPERIENCES
- Difuzní velkobuněčný B lymfom, charakteristika a léčba, data z registru Kooperativní lymfomové skupiny
- DLOUHODOBÁ REMISE MULTICENTRICKÉ CASTLEMANOVY CHOROBY U VYSOCE PŘEDLÉČENÉHO PACIENTA
- Dlouhodobé přežití po autologní transplantaci hematopoetických buněk u pacientů s mnohočetným myelomem: zkušenost jednoho centra
- DO WE KNOW AN IDEAL PATIENT WITH IMMUNE THROMBOCYTOPENIA FOR RITUXIMAB TREATMENT?
- DYNAMICS OF LINEAGE-SPECIFIC CHIMERISM IN PATIENTS AFTER NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial
- Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data
- EFFICACY AND SAFETY OF DASATINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): EUROPEAN SUBPOPULATION ANALYSIS OF THE PHASE 3 DASISION TRIAL
- EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE
- EFFICACY AND TOXICITY OF THE FLAMSA/RIC REGIMEN IN 40 PATIENTS WITH HIGH-RISK AML: A SINGLE CENTRE EXPERIENCE
- EFFICACY OF LENALIDOMIDE-BASED AND BORTEZOMIB-BASED REGIMENS IN THE FIRST RELAPSE OF 144 MULTIPLE MYELOMA PATIENTS: A SINGLE CENTRE EXPERIENCE
- EFFICACY OF THALIDOMIDE-BASED AND BORTEZOMIB-BASED REGIMENS IN THE FIRST RELAPSE OF 146 MULTIPLE MYELOMA PATIENTS: A SINGLE CENTRE EXPERIENCE
- EFFICATIOUS BUT INSIDIOUS. A RETROSPECTIVE ANALYSIS OF FLUDARABINE-INDUCED MYELOTOXICITY USING LONG-TERM CULTURES –INITIATING CELLS IN 100 FOLLICULAR LYMPHOMA PATIENTS
- ELIMINATION OF MUTATED P53 PROTEIN AND INDUCTION OF P53 DOWNSTREAM GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS USING PRIMA-1MET
- ESTIMATION OF THE CURRENT SURVIVAL MEASURES IN CHRONIC MYELOID LEUKEMIA: METHODOLOGY AND NEW SOFTWARE TOOLS
- EUTOS Score Is Also Valid in CML Patients Not Involved in Clinical Studies
- EVALUATION OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BY MULTIPARAMETRIC FLOW CYTOMETRY AND REAL-TIME PCR
- EVALUATION OF TP53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA USING RESEQUENCING MICROARRAY PLATFORMS
- Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemi
- Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
- Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma
- Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)
- FIND ´FUNGAL INFECTION DATABASE´ - RETROSPECTIVE ANALYSIS OF INVASIVE ASPERGILLOSIS IN HEMATOONCOLOGICAL DEPARTMENTS IN CZECH AND SLOVAK REPUBLIC BETWEEN 2001-2009
- FIRST INTERIM ANALYSIS OF A PAN-EUROPEAN STOP TRIAL USING STANDARDIZED MOLECULAR CRITERIA: RESULTS OF THE EURO-SKI TRIAL
- First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial O
- FOCUSED MICROARRAY FOR LYMPHOMA DIAGNOSTICS
- Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response
- GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
- GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NONHODGKIN LYMPHOMA
- Gene Mutations and Treatment Outcome in CLL Patients Treated
- Gene-Expression Profile of Steroid-Refractory Acute Graft-Versus-Host Disease
- Gene-Expression Profiling of Graft-Versus-Host Disease by Oligonucleotide Microarrays
- GENOMIC COPY NUMBER ALTERATIONS IN HIGH-RISK CLL PATIENTS HARBORING TP53 DEFECTS: INSIGHTS FROM CONSECUTIVE INVESTIGATIONS
- HIGH EFFICACY OF PULSE CYCLOPHOSPHAMIDE IN CORTICOSTEROID-REFRACTORY LIVER GRAFT-VERSUS-HOST DISEASE
- High Expression of LAG3, LPL and ZAP-70 Genes in B-CLL Strongly Correlates with Unmutated IgVH and Early Therapy Requirement
- HIGH-DOSE CYTARABINE AND MITOXANTRONE ±RITUXIMAB FOR COLLECTION OF PERIPHERAL BLOOD STEM CELLS IN HIGH-GRADE NON-HODGKINS´ LYMPHOMA. SINGLE CENTER EXPERIENCE WITH FILGRASTIM BIOSIMILARS
- HOW TO TREAT B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND BURKITT LYMPHOMA. SINGLE CENTRE EXPERIENCE.
- CHARACTERISTICS AND PROGNOSIS OF ACUTE ERYTHROLEUKEMIA (AEL) - RESULTS OF A SUBGROUP ANALYSIS OF THE STUDY ALLIANCE LEUKEMIA (SAL) AML TRIALS
- CHARACTERIZATION OF 22Q11 DELETION IN CLL PATIENTS
- CHARACTERIZATION OF P53 AND ATM ABNORMALITIES IN B-CLL PATIENTS
- CHARACTERIZATION OF T CELL RECEPTOR BETA REPERTOIRE IN T CELL POPULATION ASSOCIATED WITH GRAFT-VERSUS-HOST AND GRAFT-VERSUS-LEUKEMIA EFFECT
- Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL)
- Chimerism Status as a Possible Marker of Incipient Disease Relapse in Patients with AML.
- CHLORAMBUCIL (CHL) AND FLUDARABINE (F) AS A NEW PRE-TRANSPLANT CONDITIONING FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS OF IN VITRO AND IN VIVO EXPERIMENTS
- CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE HIGHLY SUSCEPTIBLE TO DIRECT INHIBITION OF CHECKPOINT KINASE 1
- CHRONIC MYELOID LEUKEMIA: IS THE REAL PROGNOSIS OF NEWLY DIAGNOSED PATIENTS REALLY SO GOOD?
- Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study
- IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY
- IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) – ANALYSIS OF ITS PREVALENCE, DIAGNOSTICS AND THERAPY IN THE SOUTH MORAVIAN REGION (CZECH REPUBLIC)
- IMATINIB (IMA) PLASMA CONCENTRATION (PC) MONITORING AND ITS CORRELATION WITH TREATMENT RESPONSE IN CHRONIC MYELOGENOUS LEUKEMIA (CML): A SINGLE CENTRE EXPERIENCE
- IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. CAN WE COMPARE THE REAL-LIFE DATA TO CLINICAL TRIAL RESULTS?
- IMATINIB IN THE FIRST-LINE CML TREATMENT: AN ANALYSIS OF A COMPREHENSIVE NON-COMMERCIAL DATABASE OF ALL CONSECUTIVE PATIENTS IN A DEFINED POPULATION
- Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chron
- IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR’S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY
- Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for B-cell chronic lymphocytic leukemia (BCLL).
- Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database
- IMPACT OF TREATMENT ADMINISTRATION ON SELECTION OF BCRABL1 KINASE DOMAIN MUTATIONS
- Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Incidence of CML in Europe - a Comparison of 19 European Countries with US SEER Data
- Incidence of Genomic Aberrations and Associated Efficacy from a Phase III Study Comparing Alemtuzumab (CAMPATH®, , MABCAMPATH®, ) vs Chlorambucil as First Line Therapy for B-Cell Chronic Lymphocytic Leukemia (BCLL).
- INCORPORATION OF NEXT-GENERATION SEQUENCING INTO ATM GENE ANALYSIS IN PATIENTS WITH CLL AND MCL
- Individuální rozdíly v efektivitě léčby intrakoronární transplantaci vyšší dávky buněk kostní dřeně zjištěné pomocí sestamibi SPECT/FDG PET myokardu
- Infekční komplikace léčby maligních lymfomů
- INFUSION OF HLA-MISMATCHED PERIPHERAL BLOOD STEM CELLS DURING TREATMENT AML IN ELDERLY PATIENTS
- INHIBITION OF DNA-PK SENSITIZES A PROPORTION OF CLL CULTURES TO FLUDARABINE, REGARDLESS OF THE TP53/ATM STATUS
- Inhibition of Chk1 Kinase Sensitizes Leukemia and Lymphoma Cell Lines with TP53 Mutations to Chemotherapy
- Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab
- Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study
- INTRA-ARTERIAL INJECTION OF IMMUNOSUPPRESSIVE THERAPY FOR SEVERE GASTROINTESTINAL AND LIVER GVHD
- IS LEUKAPHERESIS ABLE TO IMPROVE SURVIVAL IN HYPERLEUKOCYTIC AML IF USED AS THE EARLY CYTOREDUCTION TREATMENT?
- IS NONMYELOABLATIVE TRANSPLANT SUFFICIENT TO CURE CHRONIC MYELOID LEUKEMIA?
- JAK2 Mutation and Additional Thrombophilic Markers Predispose to Thrombosis in Myeloproliferative Diseases with Thrombocythemia
- Kooperativní lymfomová skupina (Czech Lymphoma Study Group)
- Léčba akutní myeloidní leukémie u nemocných ve věku nad 60 let. Srovnání kurativní a paliativní léčby
- LONG-TERM OUTCOMES OF AUTOLOGOUS TRANSPLANTATION IN 141 MULTIPLE MYELOMA PATIENTS: A SINGLE CENTRE EXPERIENCE
- Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Prognostic Significance of Complete Response
- LONG-TERM RESULTS OF REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR 1ST CHRONIC PHASE CML
- Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA
- Management of Relapsed/Refractory Hodgkin Lymphomas After ASCT in Czech Republic
- MECHANISM OF IMPAIRED GLUCOSE METABOLISM DURING NILOTINIB THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
- Microenvironmental Interactions up-Regulate CD20 Expression in CLL B Cells through the CXCR4/SDF-1 Axis: Implications for CD20-Targeting Antibodies and the Use of BCR-Inhibitors in Combination
- MICROCHIMERISM – LOOK INTO THE INCIPIENT AML RELAPSE?
- Microrna-34a As a Marker for Fludarabine Resistance and Impairment of p53-Pathway in Chronic Lymphocytic Leukemia
- MICRORNA-34A IS SIGNIFICANTLY DOWN-REGULATED IN B-CLL PATIENTS WITH P53 ABNORMALITIES
- MICRORNAS EXPRESSION PATTERN IN AGGRESSIVE SUBTYPE OF CHRONIC LYMPHOCYTIC LEUKEMIA
- Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders
- MISSENSE MUTATIONS LOCATED IN STRUCTURAL P53 DNA-BINDING MOTIFS ARE ASSOCIATED WITH EXTREMELY POOR SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
- Model klinického registru umožňujícího hodnocení léčebné péče: projekt ALERT (Akutní LEukémie – klinický RegisTr)
- MOLECULAR ANALYSIS OF IGVH GENE MUTATIONAL STATUS AS A PROGNOSTIC FACTOR IN B – CLL WITHIN CZECH PATIENTS
- Molecular Identification of Individual T Cell Clones Specific for Graft- Versus-Leukemia Reaction
- Molekulárně-biologické přístupy mutační analýzy genu TP53 u onkologických pacientů.
- Molekulární identifikace alodepletovaných individuálních protinádorových klonů T lymfocytů
- Molekulární identifikace T lymfocytárních klonů specifických pro reakci štěpu proti leukemii
- MONITORING OF MINIMAL RESIDUAL DISEASE IN MANTLE CELL LYMPHOMA
- Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML) – a Single Center Experience in 27 Patients
- MONITORING OF THE STATUS OF BOTH P53 ALLELES IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA - RELEVANCE TO PROGNOSIS AND TREATMENT
- MORBIDITY AND MORTALITY WITH NONMYELOABLATIVE COMPARED TO MYELOABLATIVE CONDITIONING BEFORE RELATED STEM CELL TRANSPLANTATION
- Možnosti molekulární identifikace individuálních klonů T lymfocytů zodpovědných za reakci štěpu proti nádoru při alogenních transplantacích hematopoetických kmenových buněk.
- MRD LEVEL ANALYSIS IN ADULT ALL PATIENTS. ANALYSIS OF THE CZECH LEUKEMIA STUDY GROUP–FOR LIFE (CELL)
- Multivariate and Subgroup Analyses of a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia
- MUTATION STATUS OF ATM GENE IN CLL PATIENTS HARBORING DELETION 11Q OR TP53 DEFECT
- Mutational Analysis of Mir-29 Family Members in Chronic Lymphocytic Leukemia
- Mutational Analysis of TP53 Gene in Chronic Lymphocytic Leukemia: Comparison of Different Methodological Approaches
- MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA
- Nemocniční registr onkologicky nemocných - zkušenosti Fakultní nemocnice Brno.
- NEUROMUSCULAR TOXICITY OF TYROSINE KINASE INHIBITORS IN THE THERAPY OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA
- New Characteristics of Liver Gvhd: Kinetics, and the Serum Levels of Enzymes Linked to Cholestasis
- NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HEMATOLOGICAL PRACTICE. A MULTICENTER ANALYSIS
- Nezvyklý případ podkožní pannikulitidě podobného T lymfomu
- Nezvyklý případ podkožní pannikulitidě podobného T lymfomu, kazuistika.
- NOD/SCID GAMMA XENOGRAFT MODEL OF B-CELL MALIGNANCIES USING TP53- AND/OR ATM-DEFICIENT CELL LINES
- NOD/SCID IL2RGAMMA(-/-) XENOGRAFT MODEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA
- NON-HODGKIN LYMPHOMA SUBTYPES CLASSIFICATION USING FOCUSED MICROARRAY
- NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911)
- Occurrence of Chromosomal Abnormalities In Bone Marrow CD14+ monocytes of Multiple Myeloma Patients
- Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An Internatio
- Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results
- Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)
- Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life
- Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II T
- Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.
- Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry
- OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR INTENSIVE CHEMOTHERAPY (IC) IN THE AZA-AML-001 STUDY
- P53 Inactivation and Genomic Aberrations in Relation to Imatinib Resistance in Chronic Myeloid Leukemia
- PCR DETECTION OF NON-MTC T(11;14) TRANSLOCATIONS IN MANTLE CELL LYMPHOMA
- PERCUTANEOUS KYPHOPLASTY IN THE TREATMENT OF PATHOLOGICAL VERTEBRAL BODY FRACTURES IN MULTIPLE MYELOMA PATIENTS
- PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)
- PERSISTENCE OF LYMPH NODE T(14;18) BEARING CELLS IN FOLLICULAR LYMPHOMA PATIENTS IN CLINICAL COMPLETE REMISSION: PROOF OF PRINCIPLE FOR MAINTENANCE THERAPY?
- PERSISTENT MICROCHIMERISM IN BONE MARROW: INFLUENCE OF MESENCHYMAL STEM CELLS
- PHASE 3 STUDY OF FRONTLINE RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE PLUS VINCRISTINE (R-CHOP) OR BORTEZOMIB (VR-CAP) IN TRANSPLANTATION-UNSUITABLE MANTLE CELL LYMPHOMA (MCL) PATIENTS
- Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study
- Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkins lymphoma (NHL)
- PHILADELPHIA-POSITIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: REAL LIFE OF TWO GEOGRAPHICAL REGIONS
- POSITIVE PRETRANSPLANTATION POSITRON EMISSION TOMOGRAPHY INDICATES POOR PROGNOSIS IN RELAPSED HODGKIN LYMPHOMA PATIENTS
- Post hoc analysis of association between treatment response and various indicators of efficacy and safety in a randomized phase III trial of decitabine in older patients with acute myeloid leukemia.
- Post hoc analysis of relationship between baseline white blood cell count and survival outcome in a randomized phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
- PREDICTION OF IMATINIB THERAPY RESPONSE: A ROLE OF INTRACELLULAR TRANSPORTERS HOCT-1 AND ABCB1
- Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
- PRESENCE OF HETEROZYGOUS ATM DELETION MAY NOT BE CRITICAL FOR THE RESPONSE OF CLL CELLS TO FLUDARABINE
- Principy stagingu a hodnocení léčebné odpovědi u non-hodgkinských lymfomů
- PROGNOSIS OF RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER COMBINED FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) TREATMENT
- Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts
- Prognostic Impact of NOTCH1 Hotspot Mutation in TP53-Mutated Patients with Chronic Lymphocytic Leukemia
- Prognostic Stratification of Patients with Chronic Lymphocytic Leukemia Based on Quantitative Flow Cytometry Evaluation of ZAP-70 Versus Homology of IgVH Plot
- PROGNOSTICKÝ VÝZNAM HOT SPOT MUTACE GENU NOTCH1 U PACIENTŮ S CHRONICKOU LYMFOCYTÁRNÍ LEUKEMIÍ A SOUVISLOST S MOLEKULÁRNĚ BIOLOGICKÝMI MARKERY ONEMOCNĚNÍ
- Prognostický význam mutačního stavu genu TP53 u pacientů s B-buněčnou chronickou lymfocytární leukémií – význam monitorováni obou alel.
- PROPHYLAXIS WITH FEBUXOSTAT IN COMPARISON TO ALLOPURINOL REDUCES EXPOSURE TO URIC ACID IN PATIENTS AT INTERMEDIATE TO HIGH RISK OF TUMOR LYSIS SYNDROME: RESULTS OF THE FLORENCE STUDY
- Přítomnost heterozygotní delece ATM nedeterminuje odpověď CLL buněk na fludarabin
- QUALITY OF LIFE (QOL) IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) ON IMATINIB. A PILOT STUDY.
- QUALITY OF LIFE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS INVESTIGATOR’S CHOICE: MCL-002 (SPRINT) TRIAL
- QUANTITATIVE DETECTION OF MINIMAL RESIDUAL DISEASE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA USING LNA-MODIFIED TAQ-MAN PROBES AND IGH-RQ PCR
- Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?
- REARRANGEMENT OF LAMBDA IMMUNOGLOBULIN LIGHT CHAIN IN CLL IS COUPLED WITH MIRNA-650 EXPRESSION
- RELATIONSHIP BETWEEN THERAPY AND CLONAL EVOLUTION OF TP53 ABNORMALITIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML.
- Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)
- Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
- Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience
- RITUXIMAB IN COMBINATION WITH HIGH-DOSE DEXAMETHASONE: AN EFFECTIVE TREATMENT OPTION FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
- Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
- Rituximab Sensitizes B-CLL Cells with Inactivated p53 to Fludarabine.
- RITUXIMAB SENSITIZES SOME B-CLL SAMPLES TO FLUDARABINE AND CHLORAMBUCIL IN VITRO, REGARDLESS OF P53/ATM STATUS
- ROLE OF FDG-PET IN T-CELL AND NK-CELL LYMPHOMAS
- Role of p53 Gene Mutation Type in B-CLL Prognosis
- SAFETY AND TOLERABILITY OF DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL): POOLED ANALYSIS OF OVER 2400 PATIENTS
- SALVAGE TREATMENT WITH MELPHALAN 100 MG/M2 IN FULMINANT PROGRESSION OF MULTIPLE MYELOMA
- Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)
- SENSITIZATION OF LEUKEMIC CELLS TO FLUDARABINE BY MONOCLONAL ANTIBODY RITUXIMAB - IDENTIFICATION OF RESPONSIBLE GENES
- Sequence Variations in miRNA Genes Are Common and May Affect Their Expression in Patients with Chronic Lymphocytic Leukemia
- Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT
- SF3B1 MUTATIONS AND OUTCOME IN CLL PATIENTS TREATED WITH CHLORAMBUCIL (CHL) OR OFATUMUMAB-CHL (O+CHL): RESULTS FROM THE PHASE III STUDY COMPLEMENT 1 (OMB110911)
- SF3B1 Mutations Frequently Occur With Both ATM Mutations and TP53 Mutations In CLL Patients
- SHORTENING OF NEUTROPENIA IN LYMPHOMA PATIENTS AFTER TRANSPLANTATION OF LIN ENRICHED CELLS EXPANDED EX VIVO
- Similar Efficacy of Thalidomide-Based and Bortezomib-Based Regimens In the First Relapse of 209 Multiple Myeloma Patients Previously Untreated with Novel Drugs
- Single Cell Analysis of IG Genes in CLL: Cases with Multiple IGH Rearrangements Are Constituted of Several Independent Clones Even When Indistinguishable By Flow Cytometry
- Single Cell Analysis Proves the Coexistence of NOTCH1 and TP53 Mutations within the Same Cancer Cells in Patients with Chronic Lymphocytic Leukemia
- SKIN ADVERSE EFFECTS OF TYROSINE KINASE INHIBITORS IN THE THERAPY OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA – SINGLE CENTRE EXPERIENCE
- Sledování defektů ve fosforylaci STAT1, STAT3 proteinů a jejich význam pro stanovení prognózy u CLL pacientů
- Sledování exprese vybraných genů u pacientů s B-buněčnou chronickou lymfocytární leukémií – záchyt změny leukemického klonu vlivem terapie
- Slibný účinek Bortezomibu v léčbě Hodgkinových lymfomů.
- Srovnání metod CD34+ and Lin– selekce buněk ze štěpu periferních kmenových buněk pacientů s lymfomy a vyhodnocení jejich ex vivo diferenciace pomocí cDNA microarrays.
- SROVNÁNÍ NEJČASTĚJI VYUŽÍVANÝCH METOD DETEKCE HOT SPOT MUTACE GENU NOTCH1 U PACIENTŮ S CHRONICKOU LYMFOCYTÁRNÍ LEUKEMIÍ
- Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds
- Stanovení exprese ZAP-70 metodou kvantitativní cytometrie, korelace s mutačním stavem IgVH a expresí CD38 u pacientů s diagnózou B-CLL
- Status of Minimal Residual Disease Determines Outcome of Autologous HSCT in Adults with High-Risk Acute Lymphoblastic Leukemia
- Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphoma.
- SYNTHETIC LETHALITY IN P53 MUTATED B-CELL MALIGNANCIES: CHK-1 INHIBITION AND DNA-PK INHIBITION EFFECT IN CELL LINES AND PRIMARY CLL CELLS
- T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN DAILY HEMATOLOGICAL PRACTICE
- T(14;18) IN FOLLICULAR LYMPHOMA: A REAL- TIME (PCR) FOR A REAL LIFE….?
- T315I MUTATIONS ARE CLUSTERED WITH ADVANCED PHASES CONTRARY TO OTHER ABERRATIONS IN CML PATIENTS RESISTANT TO TKI THERAPY
- TELOMERE LENGTH AND POT1 MUTATIONS IN CLL: INCIDENCE, ASSOCIATIONS AND CLINICAL IMPACT IN THE COMPLEMENT 1 TRIAL
- Terapeutické monoklonální protilátky senzitivizují in vitro některé B-CLL vzorky s aberacemi genu TP53 k fludarabinu a chlorambucilu.
- Testování monoklonální protilátky rituximab u B-CLL buněk in vitro
- THE DETECTION OF 1,3-?-D-GLUCAN DETECTION IN BRONCHOALVEOLAR LAVAGE FLUID FOR THE DIAGNOSIS OF INVASIVE PULMONARY ASPERGILLOSIS IN HEMATOLOGICAL PATIENTS
- THE DETECTION OF GALACTOMANNAN IN BRONCHOALVEOLAR LAVAGE FLUID FOR THE DIAGNOSTICS OF INVASIVE PULMONARY ASPERGILOSIS IN HEMATOONCOLOGICAL PATIENTS
- THE EUTOS POPULATION BASED REGISTRY – INCIDENCES OF CML ACROSS EUROPE
- THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES
- THE EXPRESSION OF A SINGLE MICRORNA - MIR-34A – IS A RELIABLE MARKER FOR IMPAIRMENT OF P53-PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA
- The Gene Expressions of hOCT1 and ABCB1 Change During the Course of CML in Relation to Imatinib Therapy
- THE IMPACT OF SPECIFIC MUTATIONS IN TP53 GENE ON THE RESULTS OF ALEMTUZUMAB THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
- THE LATE CARDIOTOXICITY OF DOXORUBICIN CONTAINING REGIMENS IN THE TREATMENT OF MALIGNANT LYMPHOMAS
- The Mystery of FDG-PET Avidity In Follicular Lymphoma. Does Microenvironment Play the Key Role?
- The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program
- The Plateau of BCR-ABL Transcript Level =;>0.1% May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis.
- THE PROSPECTIVE ANALYSIS OF LOW LEVEL BCR-ABL1 T315I MUTATION IN THE CD34+ CELLS OF DE NOVO CML PATIENTS
- The Regulation, Targets and Clinical Relevance of Microrna Mir-650 in Chronic Lymphocytic Leukemia (CLL)
- Torakoskopický odběr mediastinálních infiltrátů.
- TP53 Abnormalities in Chronic Lymphocytic Leukemia Exhibit a Disease Specific Profile: Meta-Analysis of 270 Mutations
- TP53 MUTATIONS BUT NOT ATM MUTATIONS ASSOCIATE WITH HIGHER IN VITRO RESISTANCE OF CLL CELLS TO RITUXIMAB
- TRANSLOCATION IS A FREQUENT MECHANISM FOR 17P DELETION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry
- TREATMENT OF MOLECULAR RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
- TREATMENT OF MOLECULAR RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
- TREATMENT OF PHILADELPHIA-POSITIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN REAL LIFE: EXPERIENCE OF ONE CENTRE
- TUMOR DYNAMICS OF CHRONIC LYMPHOCYTIC LEUKEMIA CASES WITH MULTIPLE PRODUCTIVE IGHV-IGHD-IGHJ REARRANGEMENTS
- UNEXPECTED ANTAGONISTIC EFFECT OF RITUXIMAB WITH PROCARBAZINE DISCLOSED DURING AN IN VITRO TESTING OF RITUXIMAB-MEDIATED SENSITIZATION OF B-CELL LINES TO COMMONLY USED ANTICANCER DRUGS
- UP-FRONT SALVAGE TREATMENT WITH MELPHALAN 100 MG/M2 IN FULMINANT PROGRESSION OF MULTIPLE MYELOMA AND CONSOLIDATION WITH NOVEL DRUGS
- USEFULNESS OF THE VORICONAZOLE PLASMA LEVELS MONITORING IN HEMATOONCOLOGICAL PTS TREATED BY ORAL FORM OF THE VORICONAZOLE
- Úskalí molekulární diagnostiky Ewingova sarkomu / PNET
- VALIDATION OF THE EUTOS SCORE FOR PREDICTION OF COMPLETE CYTOGENETIC RESPONSE AND PROGRESSION FREE SURVIVAL: APPLICATION TO INDEPENDENT DATA FROM THE EUTOS REGISTRY AND REVIEW OF PUBLICATIONS
- VORICONAZOLE PLASMA LEVELS AND GENETICS POLYMORPHISM OF CYP2C19 IN HEMATOONCOLOGICAL PATIENTS
- VYHLEDÁVÁNÍ A SLEDOVÁNÍ KLONŮ S MUTACÍ TP53 V CHRONICKÉ FÁZI MYELOPROLIFERATIVNÍCH NEOPLAZIÍ (MPN)
- Využití DNA microarrays v diagnostice lymfocytárních leukémií.
- Využití long-oligonucleotide arrayCGH v diagnostice leukémií.
- Využití RNA interference při regulaci genové exprese antionkogenu p53
- Využití RNA interference při regulaci genové exprese antionkogenu p53
- WHAT CAN WE CURRENTLY LEARN FROM NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HAEMATOLOGICAL PRACTICE?
- WHAT DO WE KNOW ABOUT THE REAL INCIDENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND WHERE AND HOW ARE THE PATIENTS WITH CLL TREATED?
- What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?
Články v Klinické onkologii
- Autologní transplantace kostní dřeně u nemocných s chronickou myeloidní leukemií
- Autologní transplantace s podáním interleukinem 2 aktivovaného štěpu periferních kmenových buněk nemocným s chronickou myeloidní leukemií
- CAMPATH-1H (alemtuzumab) v léčbě leukemií a v modulaci imunity
- Castlemanova choroba
- Castlemanova choroba: retrospektivní studie léčebných výsledků u 10 pacientů z jednoho centra
- Cefoperazon plus sulbaktam v léčbě febrilní neutropenie a infekcí u onkologických pacientů
- Clostridium difficile Associated Diarrhoea – problém onkologického pacienta
- Cytogenetické vyšetření lymfocytů periferní krve po stimulaci IL-2 a CpG oligonukleotidem DSP30 u pacientů s chronickou lymfocytární leukemií
- Další plicní onemocnění
- Diagnostické možnosti
- Edém plic - 1.část
- Edém plic - 2.část
- Febrilní neutropenie u onkologicky nemocných
- Filgrastim a akutní myeloidní leukemie
- Fludarabin v léčbě folikulárních lymfomů
- Chlorhexidin v profylaxi a léčbě ústních komplikací protinádorové chemoterapie
- Indikace k alogenním a autologním transplantacím krvetvorných buněk. Doporučení České hematologické společnosti ČLS JEP a České onkologické společnosti ČLS JEP.
- Indukční léčba nemocných s akutní myeloidní leukémií protokolem ICE
- Infekce způsobené grampozitivními bakteriemi u onkologicky nemocných a význam vankomycinu v jejich léčbě
- Inhibice signalizace B buněčným receptorem: první cílená léčba u chronické lymfocytární leukemie a dalších B buněčných lymfomů
- Jaká je optimální terapie mladších nemocných s akutní myeloidní leukémií?
- Léčba anakinrou u Schnitzler-syndromu-výsledky první retrospektivní multicentrické studie šesti pacientů z České republiky
- Léčba folikulárních lymfomů: současný stav a nové trendy
- Léčba histiocytózy z Langerhansových buněk kladribinem dosáhla u 9 z 10 dospělých pacientů dlouhodobé kompletní remise
- Léčba pacientů s relabovaným/refraktérním Hodgkinovým lymfomem
- Mini Dexa BEAM jako druhý záchranný režim u nemocných s lymfomy po selhání první, na ifosfamidu a etoposidu založené chemoterapii
- Množství mononukleárních buněk není spolehlivé pro hodnocení kvality transplantátu periferních kmenových buněk
- Model populačního klinického registru umožň ujícího hodnocení léčebné péče: projekt ALERT (akutní leukemie-klinický registr)
- Molekulárně biologická diagnostika mutací genu KRAS a BRAF u pacientů s kolorektálním karcinomem – zkušenosti laboratorního pracoviště
- Molekulárně genetické vyšetření u akutní myeloidní leukemie
- MST Mundipharma - nový preparát pro léčbu bolesti onkologicky nemocných
- Nádorový supresor p53 a leukémie
- Nahradí transplantace alogenních kmenových krvetvorných buněk periferní krve kostní dřeň?
- Nefrotoxicita konvenčního Amfotericinu B u onkologicky nemocných a možnosti její profylaxe
- Nové léky v terapii akutní myeloidní leukemie u starších pacientů
- Od genomu k proteomu využití proteinových čipů v onkologii
- Odběr a zpracování vzorků pro expresní DNA čipy
- Oncology in Images
- Onkologie v obrazech. Makroglosie jako příznak onemocnění kostní dřeně
- Parciální regrese ložisek Erdheimovy-Chesterovy nemoci v CNS po léčbě 2-chlorodeoxyadenosinem a jejich kompletní vymizení při léčbě lenalidomidem
- Perspektivy imunoterapie v léčbě mnohočetného myelomu
- Plicní komplikace způsobené infekcemi - obecné aspekty
- Postižení plic vlastním nádorovým procesem
- Postižení plic vlastním nádorovým procesem při lymfomech a dalších hematologických onemocněních
- Poškození způsobená léčebnými zákroky
- Poškození způsobená léčebnými zákroky - dokončení - Plicní hemoragie
- Poznámky k některým mikroorganismům vyvolávajícím pneumonie - 1.část
- Poznámky k některým mikroorganismům vyvolávajícím pneumonie - 2.část
- Poznámky k některým mikroorganismům vyvolávajícím pneumonie - 3.část
- Poznámky k některým mikroorganismům vyvolávajícím pneumonie - 4.část
- Profylaxe časných komplikací spojených s alogenní transplantací krvetvorných progenitorových buněk periferní krve nebo kostní dřeně
- Proteomická analýza nádorových buněk
- Přehled zkušeností s vysokodávkovou chemoterapií následovanou autologní transplantací krvetvorných buněk u pacientů s folikulárními lymfomy a s lymfomem z plášťových buněk
- Recidivující krvácení z jater a hemoperitoneum jako následek masivního postižení AL amyloidózou: popis případu a přehled literatury
- Regrese osteolytického ložiska u pacienta s mnohočetným myelomem léčeného klodronátem po úspěšné terapii režimem s bortezomibem
- Relaps mnohočetného myelomu - jaké léčebné možnosti máme?
- Retransplantace u nemocných s mnohočetným myelomem (MM) relabujícím po první autologní transplantaci (Pilotní studie CMG)
- Rozvaha nad dávkováním cytostatik u obézních nemocných
- Schnitzler-syndrom: diagnostika a léčba
- Symptomatická parenterální antipyretická léčba u onkologických nemocných - srovnání metamizolu, diclofenacu a propacetamolu
- Šestileté sledování pacienta s mnohočetnou angiomatózou postihující skelet, břišní i hrudní dutinu a stěnu trávicí trubice
- Těhotenství a leukémie
- Terapie mnohočetného myelomu: zhodnocení přínosu vysokodávkované chemoterapie, interferonu alfa a bisfosfonátů
- Tropisetron v profylaxi nevolnosti a zvracení u pacientů s vysokodávkovanou chemoterapií
- Virové infekce u onkologicky nemocných
- Vliv onkologické léčby na lidskou reprodukci
- Vysokodávkovaná léčba mnohočetného myelomu s transplantací autologních kmenových hemopoetických buněk a následující udržovací léčbou interferonem alfa versus interferonem alfa a dexametazonem - randomizovaná klinická studie
- Využití bronchoalveolární laváže - obecné poznámky
- Využití bronchoalveolární laváže u jednotlivých plicních postižení
- Využití rituximabu v léčbě chronické lymfatické leukemie
- Záchranné a periferní kmenové buňky mobílizující chemoterapie založená na kombinaci ifosfamidu a etoposidu u nemocných lymfomem se špatnou prognózou
- Zpráva z mezinárodních sympozií o mnohočetném myelomu - Vlllth International Myeloma Workshop Banff, Alberta. Kanada 4.-8. 5.2001.
- Zpráva ze studijního pobytu v Berlíně
Léčebné postupy
- Antibiotická profylaxe u hematoonkologických nemocných – doporučení odborníků s podporou CELL
- Empirická antimykotická léčba febrilní neutropenie u nemocných s hematologickou malignitou
- Empirická liečba febrilnej neutropénie u onkohematologických pacientov - odporúčanie odborníkov s podporou CELL
- Léčebné postupy v hematologii (tzv. "Červená kniha")
- Postupy diagnostiky a léčby leukemií a jejich infekčních komplikací u dospělých pacientů. Doporučení České leukemické skupiny – pro život (CELL)
